The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.125
Bid: 6.00
Ask: 6.25
Change: 0.50 (8.89%)
Spread: 0.25 (4.167%)
Open: 5.625
High: 7.25
Low: 5.125
Prev. Close: 5.625
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Apr 2021 07:00

RNS Number : 1755U
Genedrive PLC
01 April 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

 

 

Total Voting Rights

 

Genedrive plc (AIM: GDR) notifies the market that as at 31 March 2021 the Company's issued share capital comprises 63,320,048 ordinary shares with voting rights ('Shares'). No Shares are held in Treasury. As such, the number of Shares with voting rights is 63,320,048.

 

This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Victoria Erskine

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKDBKQBKDPNN
Date   Source Headline
24th Apr 20243:36 pmRNSClinical Trial Agreement
3rd Apr 20245:00 pmRNSApplication for Listing & Total Voting Rights
3rd Apr 20247:00 amRNSNICE recommends the Genedrive CYP2C19-ID Kit
28th Mar 20247:00 amRNSHalf-year Report
26th Mar 20247:00 amRNSInvestor presentation
19th Mar 20243:53 pmRNSApplication for Listing & Total Voting Rights
15th Mar 202412:30 pmRNSReceipt of R&D tax credit
19th Feb 20247:00 amRNSNICE Early Value Assessment update
6th Feb 20242:03 pmRNSDirector/PDMR Shareholding
2nd Feb 20243:35 pmRNSTotal Voting Rights
19th Jan 20244:14 pmRNSTotal Voting Rights
15th Jan 20243:21 pmRNSTotal Voting Rights
10th Jan 20247:00 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSEquity Prepayment Facility drawdown
29th Dec 202311:44 amRNSResult of AGM
20th Dec 20234:57 pmRNSTotal Voting Rights
20th Dec 20237:00 amRNSInitial overseas orders of MT-RNR1 ID kit
7th Dec 20237:00 amRNSTotal Voting Rights
6th Dec 20237:00 amRNSPosting of annual report and notice of AGM
6th Dec 20237:00 amRNSTotal Voting Rights
4th Dec 20231:13 pmRNSMT-RNR1 ID kit adopted for routine use in Brighton
30th Nov 20235:29 pmRNSBlock listing Interim Review
30th Nov 20237:00 amRNSFinal Results
29th Nov 20235:25 pmRNSEquity Prepayment Facility drawdown
16th Nov 20237:00 amRNSNotice of Results
20th Oct 202310:52 amRNSTotal Voting Rights
28th Sep 202312:35 pmRNSc£1.2m grant awarded
21st Sep 20232:39 pmRNSApplication for listing & total voting rights
11th Sep 20232:17 pmRNSBoard changes
6th Sep 20237:00 amRNSUKCA marking achieved for new CYP2C19 test
4th Aug 20234:00 pmRNSTotal Voting Rights
5th Jul 20239:11 amRNSEquity Prepayment Facility drawdown
16th Jun 20232:28 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSMulti-partner grant awarded
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.